ESTRO 2025 - Abstract Book

S381

Brachytherapy - Urology

ESTRO 2025

Multivariate analysis revealed that elevated PSA levels were significantly associated with an increased risk of biochemical recurrence (HR 1.006; p=0.016). Although the Gleason score showed a trend toward higher recurrence risk, it did not reach statistical significance (HR 1.496; p=0.074). According to adverse events, Grade 2 or higher adverse events were observed in 17 patients. Specifically, Grade 3 acute urinary toxicity occurred in 2 patients, while one patient experienced Grade 3 late urinary toxicity. Additionally, Grade 2 acute urinary toxicity was observed in 10 patients, and Grade 2 late urinary toxicity in 2 patients. Rectal bleeding of Grade 2 severity was also noted in 2 patients. All adverse events improved with conservative management. Conclusion: The HDR-BT and hypofractionated EBRT combination provides excellent long-term disease control with acceptable toxicity levels. PSA was identified as a significant prognostic factor for biochemical recurrence. In the future, more extensive prospective studies are needed to perform detailed subgroup analyses of patient populations and identify toxicity predictors.

Keywords: Hypofractionated External Beam Radiotherapy

2478

Digital Poster Salvage High-Dose-Rate Brachytherapy for Local Recurrent Prostate Cancer: survival and toxicity of a necessary therapeutic option. Lucia Biscari García 1 , Irene Martínez Montesinos 1 , Ignacio Visus Fernández de Manzanos 1 , Naiara Fuentemilla Urío 2 , Paola Anna Jablonska 1 , Santiago Pellejero Pellejero 2 , Alberto Lacunza Carnicer 3 , María Cerrolaza Pascual 3 , Marta Barrado Los Arcos 1 , Amaya Sola Galarza 1 , Sonia Flamarique Andueza 1 , Patricia Lorenzana Moreno 1 , Maria Isabel Martínez Fernández 1 , María Ujué Ruiz Martínez de Azagra 1 , Libe Amondarain Elgarresta 1 , Darwin Enrique Pozo Jiménez 1 , Sara López García 1 , Lidia Gómez Perea 4 , Raquel Villanueva Goyeneche 1 , Esther Francés Tirapu 1 , Agustina Méndez Villamón 3 , Elena Villafranca Iturre 1 1 Radiation Oncology, Hospital Universitario de Navarra, Pamplona, Spain. 2 Radiophysics, Hospital Universitario de Navarra, Pamplona, Spain. 3 Radiation Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain. 4 Radiation Oncology, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain Purpose/Objective: High-dose-rate brachytherapy (HDR-BT) represents a salvage treatment option for patients with locally recurrent prostate cancer (Re-PCa). However, its effectiveness in terms of duration of response and toxicity profile are of concern. Our objective was to analyse the overall survival and toxicity in patients treated with salvage HDR-BT in our institution.